305 related articles for article (PubMed ID: 30910850)
1. Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer.
Feng X; Li L; Wang L; Luo S; Bai X
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30910850
[TBL] [Abstract][Full Text] [Related]
2. HOXB4 promotes the malignant progression of ovarian cancer via DHDDS.
Li N; Gou JH; Xiong J; You JJ; Li ZY
BMC Cancer; 2020 Mar; 20(1):222. PubMed ID: 32178630
[TBL] [Abstract][Full Text] [Related]
3. CHTOP in Chemoresistant Epithelial Ovarian Cancer: A Novel and Potential Therapeutic Target.
Feng X; Bai X; Ni J; Wasinger VC; Beretov J; Zhu Y; Graham P; Li Y
Front Oncol; 2019; 9():557. PubMed ID: 31380263
[No Abstract] [Full Text] [Related]
4. SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway.
Zhu W; Niu J; He M; Zhang L; Lv X; Liu F; Jiang L; Zhang J; Yu Z; Zhao L; Bi J; Yan Y; Wei Q; Huo H; Fan Y; Chen Y; Ding J; Wei M
J Transl Med; 2019 Aug; 17(1):259. PubMed ID: 31395064
[TBL] [Abstract][Full Text] [Related]
5. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
6. Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer.
Sun P; Song Y; Liu D; Liu G; Mao X; Dong B; Braicu EI; Sehouli J
Sci Rep; 2018 Sep; 8(1):13483. PubMed ID: 30194340
[TBL] [Abstract][Full Text] [Related]
7. Gli affects the stemness and prognosis of epithelial ovarian cancer via homeobox protein NANOG.
Zhao H; Li N; Pang Y; Zhao J; Wu X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33313950
[TBL] [Abstract][Full Text] [Related]
8. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
9. Impact of Selected Signaling Proteins on SNAIL 1 and SNAIL 2 Expression in Ovarian Cancer Cell Lines in Relation to Cells' Cisplatin Resistance and EMT Markers Level.
Kielbik M; Szulc-Kielbik I; Klink M
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478150
[TBL] [Abstract][Full Text] [Related]
10. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
12. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
13. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
14. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
15. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.
Tang W; Ren A; Xiao H; Sun H; Li B
Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706
[TBL] [Abstract][Full Text] [Related]
16. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
17. METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
Wu GJ; Zeng GF
BMC Cancer; 2016 Feb; 16():136. PubMed ID: 26906545
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo.
Zeng S; Liu S; Feng J; Gao J; Xue F
Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184
[TBL] [Abstract][Full Text] [Related]
19. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
